EyePoint Pharmaceuticals, Inc. — Director's Dealing 2016

Mar 22, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: pSivida Corp. (PSDV)
CIK: 0001314102
Period of Report: 2016-03-18

Reporting Person: Ashton Paul (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-03-18	Common Stock	M	10000	$1.13	Acquired	450741	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-03-18	Stock Option (Right to Buy)	$1.13	M	10000	Disposed	2018-11-18	Common Stock (10000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	16781	Indirect

Footnotes

F1: The option was granted on 11/18/2008 and vested in four equal annual installments beginning on the first anniversary of the date of grant.

F2: Shares held by the Paul Ashton Children's Irrevocable Trust, of which the Reporting Person's minor children are the beneficiaries. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest, if any, therein.